← All trials
NCT00042770
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2002
- Primary completion
- Feb 28, 2005
- Completion date
- Feb 29, 2008
- First posted
- Jan 27, 2003
- Last posted
- Jul 4, 2016
- Enrollment
- 67
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- National Cancer Institute (NCI)Collaborator
- State University of New York, BuffaloStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.